These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8846622)

  • 1. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.
    Flockhart DA
    Clin Pharmacokinet; 1995; 29 Suppl 1():45-52. PubMed ID: 8846622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24.
    Lau PS; Leong KV; Ong CE; Dong AN; Pan Y
    Biochem Genet; 2017 Feb; 55(1):48-62. PubMed ID: 27578295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.
    Steere B; Baker JA; Hall SD; Guo Y
    Drug Metab Dispos; 2015 Jun; 43(6):870-83. PubMed ID: 25845826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles.
    Foti RS; Wahlstrom JL
    Drug Metab Dispos; 2008 Mar; 36(3):523-8. PubMed ID: 18048485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.
    Krausz KW; Goldfarb I; Buters JT; Yang TJ; Gonzalez FJ; Gelboin HV
    Drug Metab Dispos; 2001 Nov; 29(11):1410-23. PubMed ID: 11602516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
    Atkinson A; Kenny JR; Grime K
    Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.
    Foti RS; Rock DA; Han X; Flowers RA; Wienkers LC; Wahlstrom JL
    J Med Chem; 2012 Feb; 55(3):1205-14. PubMed ID: 22239545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].
    Lou YQ; Kuang TY
    Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
    Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.
    Lee SJ; Kim WY; Kim H; Shon JH; Lee SS; Shin JG
    Drug Metab Dispos; 2009 Nov; 37(11):2262-9. PubMed ID: 19661214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
    Ko JW; Sukhova N; Thacker D; Chen P; Flockhart DA
    Drug Metab Dispos; 1997 Jul; 25(7):853-62. PubMed ID: 9224780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
    Koyama E; Chiba K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
    Puozzo C; Lens S; Reh C; Michaelis K; Rosillon D; Deroubaix X; Deprez D
    Clin Pharmacokinet; 2005; 44(9):977-88. PubMed ID: 16122284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
    Chang SY; Chen C; Yang Z; Rodrigues AD
    Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
    Daniel HI; Edeki TI
    Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population.
    Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
    Curr Mol Pharmacol; 2020; 13(3):233-244. PubMed ID: 31713493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.